Comment on the manuscript ‘Disproportionality analysis of cardiac adverse events associated with sorafenib using Spontaneous Reporting Database in Japanese’

Key Points

• The comment addresses the safety profile of sorafenib, particularly focusing on cardiac adverse events reported.
• Utilization of a spontaneous reporting database in Japan to analyze reported cardiac events associated with sorafenib.
• Disproportionality analysis conducted to identify any significant safety signals.
• Highlighted instances of cardiac adverse events linked to sorafenib use, suggesting increased risk.
• Discussed the implications of these findings for clinical practice and patient management.